Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOVUE-128 vs ANDRODERM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isovue-128 (iopamidol) is a nonionic, water-soluble, radiographic contrast medium that enhances imaging by attenuating X-rays, thereby increasing contrast between vascular structures and surrounding tissues. Its mechanism is based on the high iodine content which absorbs X-rays, allowing visualization of blood vessels and organs during angiography, urography, and CT scans.
Testosterone is an androgen receptor agonist; it binds to androgen receptors, leading to changes in gene expression that promote male secondary sexual characteristics and maintain libido, muscle mass, and bone density.
Intravascular use for computed tomography (CT) imaging,Intravenous urography,Intra-arterial angiography (including coronary, peripheral, and cerebral),Ventriculography,Myelography (subarachnoid injection for spinal imaging),Off-label: Arthrography, hysterosalpingography (though not FDA-approved for these)
FDA-approved: testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). Off-label: delayed puberty in males, female-to-male transgender hormone therapy.
Adult: 50-200 m L (0.5-2.0 m L/kg) intravenously, single dose for contrast-enhanced CT; for angiography, dose and rate vary by procedure.
Apply one 2.5 mg or 5 mg transdermal system to clean, dry, intact skin on the abdomen, upper arms, or thighs once daily, preferably in the morning. Starting dose is 5 mg daily; adjust based on serum testosterone levels.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours with GFR <30 m L/min).
Terminal elimination half-life is approximately 10–100 minutes (rapid), but due to transdermal absorption, effective half-life is extended to about 8–10 hours after patch application.
Iopamidol is not metabolized and is excreted unchanged almost entirely by the kidneys via glomerular filtration. No hepatic metabolism or significant protein binding occurs.
Testosterone is metabolized primarily in the liver via CYP3A4 and CYP2C9 isoenzymes, as well as by 5α-reductase to dihydrotestosterone (DHT) and by aromatase to estradiol.
Renal: >95% excreted unchanged in urine via glomerular filtration; fecal/biliary: <5%.
Approximately 90% of testosterone metabolites are excreted in urine as glucuronide and sulfate conjugates; 6% are excreted in feces via bile.
Minimal protein binding (<5%), primarily to albumin.
Approximately 98–99% bound: primarily to sex hormone-binding globulin (SHBG, ~40%) and albumin (~60%).
Approximately 0.2-0.3 L/kg, reflecting distribution into extracellular fluid.
Volume of distribution is approximately 0.2–0.8 L/kg, reflecting distribution into steroid-sensitive tissues and binding proteins.
Not applicable for oral route (no oral formulation); 100% bioavailability via intravenous or intra-arterial administration.
Transdermal bioavailability is approximately 10–15% of the nominal dose (based on 24-hour application), with interindividual variability due to skin permeability.
GFR <30 m L/min: use lowest feasible dose; GFR <15 m L/min: avoid use unless essential; consider hydration and N-acetylcysteine.
No specific dose adjustment recommended for renal impairment. Use with caution in patients with severe renal impairment due to potential fluid retention.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to risk of contrast-induced nephropathy.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), use with caution and monitor liver function; no specific dose adjustment guidelines.
Neonates: 0.5-1 m L/kg IV; Infants/Children: 1-2 m L/kg IV (max 125 m L per dose) for contrast-enhanced CT.
Not indicated for use in pediatric patients. Safety and efficacy have not been established in children <18 years.
Reduce dose to lowest effective (e.g., 50-100 m L); ensure adequate hydration; monitor renal function pre and post administration.
Initiate at 2.5 mg once daily in elderly patients due to increased risk of adverse effects, particularly prostatic hyperplasia and cardiovascular events. Monitor serum testosterone levels and adjust as needed.
Iodinated contrast media including iopamidol are associated with an increased risk of contrast-induced acute kidney injury (CI-AKI) in patients with pre-existing renal impairment, particularly those with diabetes, volume depletion, or concurrent use of nephrotoxic drugs. Strict adherence to hydration protocols and renal monitoring is required.
WARNING: Cardiovascular risk - Increased risk of myocardial infarction, stroke, and cardiovascular death has been reported with testosterone replacement therapy. Only use in men with confirmed hypogonadism.
Risk of contrast-induced nephropathy (CIN): Monitor renal function before and after administration, ensure adequate hydration, and avoid concurrent nephrotoxic agents.,Severe hypersensitivity reactions (e.g., anaphylaxis, bronchospasm): Have resuscitation equipment available; premedication may be considered for patients with known contrast allergy.,Thyroid dysfunction: Iodinated contrast may induce hyperthyroidism or hypothyroidism; caution in patients with thyroid disease.,Cardiovascular events: In patients with heart failure, coronary artery disease, or pulmonary hypertension, contrast media can cause hemodynamic instability, arrhythmias, or myocardial ischemia.,Neurologic effects: Intrathecal administration may cause seizures, arachnoiditis, or aseptic meningitis; use lowest possible dose and monitor for neurotoxicity.,Extravasation: Risk of tissue necrosis; administer through a secure IV line and monitor injection site.
Elderly patients and those with known cardiovascular risk factors should be monitored for cardiovascular events.,May exacerbate sleep apnea in predisposed individuals.,Can cause erythrocytosis; monitor hematocrit.,May accelerate growth of prostate cancer and benign prostatic hyperplasia; monitor prostate-specific antigen (PSA).,Monitor for signs of virilization in women if used off-label.,Possible hypercalcemia in immobilized patients.
Absolute: Known hypersensitivity to iopamidol, other iodine-containing contrast media, or any component of the formulation.,Absolute: Intrathecal administration in patients with significant thrombophlebitis or infection at the injection site.,Relative: Pre-existing renal impairment (e GFR <30 m L/min/1.73m²) unless benefits outweigh risks; consider alternative imaging.,Relative: Multiple myeloma, pheochromocytoma, sickle cell disease (due to risk of vaso-occlusive events).,Relative: Pregnancy (especially first trimester) unless essential for diagnosis.
Men with carcinoma of the breast or known or suspected carcinoma of the prostate.,Women who are pregnant or may become pregnant (risk of virilization of fetus).,Hypersensitivity to testosterone or any component of the product.,Severe renal or hepatic impairment (risk of fluid retention).
No specific food interactions. However, patients are often advised to maintain adequate hydration. Avoid alcohol consumption for 24 hours before and after the procedure as it may increase risk of dehydration. No dietary restrictions required.
No known food interactions. Take with or without food.
Iodinated contrast agents, including iopamidol (ISOVUE-128), are generally considered low risk for teratogenicity in humans based on limited data. In the first trimester, there is a theoretical risk of fetal hypothyroidism due to free iodide, but clinical evidence does not show a significant increase in congenital anomalies. Second and third trimester exposure is associated with transient neonatal hypothyroidism if the agent crosses the placenta, but no structural teratogenic effects are documented. The FDA assigns a Pregnancy Category B for iodinated contrast agents.
Androderm (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of pseudohermaphroditism in female fetuses (labial fusion, clitoromegaly) with androgen exposure during critical period of genital differentiation (weeks 8-12). Second and third trimesters: risk of clitoral enlargement, advanced bone age, and potential long-term behavioral effects. Male fetuses may experience premature sexual development. No adequate studies; USP pregnancy category X.
Iopamidol is excreted into breast milk in very small amounts. The milk-to-plasma (M/P) ratio is approximately 0.04–0.08 based on limited studies. The absolute dose received by a nursing infant is estimated to be less than 0.01% of the maternal dose, which is clinically insignificant. Therefore, breastfeeding can be continued without interruption, although some experts suggest discarding milk for 24 hours post-administration as a precaution. No adverse effects on the infant have been reported.
Testosterone is excreted into human milk; M/P ratio not established. Potential for virilization of female infants and early puberty in male infants. Risk of suppression of maternal lactation (androgen-induced decrease in prolactin). Contraindicated during breastfeeding; alternative therapies recommended.
No dosing adjustments are required for iopamidol (ISOVUE-128) during pregnancy based on pharmacokinetic changes. However, because physiological changes in pregnancy (increased plasma volume, increased renal clearance) may affect contrast agent distribution and elimination, the standard dose should be used based on body weight and indication. The lowest effective dose should be administered to minimize fetal exposure. No specific dose modifications are recommended in guidelines.
Androderm is contraindicated in pregnancy; no dose adjustments applicable. If therapy is necessary for maternal hypogonadism, discontinue immediately upon pregnancy recognition. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are irrelevant due to contraindication. Do not dose in pregnancy.
ISOVUE-128 (iopamidol) is a nonionic, low-osmolality contrast medium. Pre-warming to body temperature reduces viscosity and improves patient tolerance. Risk of contrast-induced nephropathy (CIN) increases with pre-existing renal impairment; assess renal function (e GFR) prior to administration. Adequate hydration is critical. Monitor for delayed hypersensitivity reactions (up to 7 days). Metformin should be withheld for 48 hours post procedure if renal function is compromised. Have emergency equipment available for anaphylactoid reactions.
Apply to clean, dry, intact skin on the abdomen, thighs, upper arms, or back. Rotate application sites to minimize skin reactions. Do not apply to genitals or scrotum. Avoid showering or swimming for at least 3-4 hours after application to ensure absorption. Monitor serum testosterone levels 14 days after starting therapy or dose adjustment, drawn in the morning before application. Use with caution in patients with known or suspected prostate cancer or breast cancer. Warn patients about the risk of transfer to women and children through skin contact; cover application site with clothing or wash skin before contact.
Inform your healthcare provider if you have any allergies, especially to contrast media or iodine.,Tell your provider about all medications you take, particularly metformin or any kidney-affecting drugs.,You may be asked to drink extra fluids before and after the procedure to protect your kidneys.,Report any symptoms like hives, itching, difficulty breathing, or swelling of the face/throat immediately.,If you have diabetes and take metformin, your doctor may advise stopping it for 48 hours after the scan.,Sensation of warmth, a metallic taste, or nausea during injection is common and usually resolves quickly.,After the procedure, you can resume normal diet unless directed otherwise.
Apply the gel to clean, dry, intact skin once daily in the morning.,Rotate application sites to prevent skin irritation.,Avoid direct skin contact with women and children; wash hands thoroughly after application and cover the site with clothing.,Do not apply to the genitals or scrotum.,Do not shower or swim for at least 3-4 hours after application.,Monitor for signs of skin irritation, such as redness or itching.,Report any swelling of the ankles, difficulty breathing, or changes in mood or sleep.,Keep the medication away from children and pets.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOVUE-128 vs ANDRODERM, answered by our medical review team.
ISOVUE-128 is a Contrast Media that works by Isovue-128 (iopamidol) is a nonionic, water-soluble, radiographic contrast medium that enhances imaging by attenuating X-rays, thereby increasing contrast between vascular structures and surrounding tissues. Its mechanism is based on the high iodine content which absorbs X-rays, allowing visualization of blood vessels and organs during angiography, urography, and CT scans.. ANDRODERM is a Androgen that works by Testosterone is an androgen receptor agonist; it binds to androgen receptors, leading to changes in gene expression that promote male secondary sexual characteristics and maintain libido, muscle mass, and bone density.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOVUE-128 and ANDRODERM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOVUE-128 is: Adult: 50-200 m L (0.5-2.0 m L/kg) intravenously, single dose for contrast-enhanced CT; for angiography, dose and rate vary by procedure.. The standard adult dose of ANDRODERM is: Apply one 2.5 mg or 5 mg transdermal system to clean, dry, intact skin on the abdomen, upper arms, or thighs once daily, preferably in the morning. Starting dose is 5 mg daily; adjust based on serum testosterone levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOVUE-128 and ANDRODERM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOVUE-128 is classified as Category C. Iodinated contrast agents, including iopamidol (ISOVUE-128), are generally considered low risk for teratogenicity in humans based on limited data. In the first trimester, there is . ANDRODERM is classified as Category C. Androderm (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of pseudohermaphroditism in female fetuses (labial fusion, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.